Test-prop 100 100mg/ml 10ml Vial by Master Pharma

Usage

1. Map your full training programme (accumulation → intensification → transition) before the cycle begins, assigning target weekly set volumes and intensity zones to each phase.
2. Match your starting dose to the accumulation phase target — typically 300–400mg/week split into three equal injections using a 23–25G needle into the glute or lateral quad.
3. At each phase transition (weeks 5 and 9), reduce your training volume first, then step down the dose by 25–50mg per week across two injection intervals to allow plasma levels to track the load reduction.
4. Log both training metrics (total weekly sets, average load percentage) and injection dates together in a single training diary; this dual log makes dose–performance correlations visible and actionable.
5. During the transition phase, draw 0.5ml (50mg) per injection using a 1ml insulin syringe for precision; the 100mg/ml concentration makes each 0.1ml exactly 10mg, facilitating fine-grained taper steps.
6. Begin PCT three to five days after the final injection, consistent with the propionate ester's clearance window, and maintain a deload or low-volume maintenance training block during PCT to allow HPG-axis recovery without complete detraining.

Warnings

Frequently asked questions

How should I structure my training programme around a Testosterone Propionate cycle?

Divide your programme into three phases — accumulation, intensification, and transition — and align each with a corresponding dose tier. Accumulation favours higher volume (18–24 sets per muscle group weekly) at moderate loads; intensification cuts volume by 30–40% and raises intensity to 80–90% 1RM; the transition phase tapers both training load and propionate dose simultaneously, exploiting the ester's fast clearance to manage aromatase substrate.

What training frequency works best with an every-other-day Testosterone Propionate injection schedule?

A three-to-four-day-per-week training frequency aligns naturally with EOD injections. Each injection maintains plasma testosterone within the anabolic window during the 48-to-72-hour post-training muscle-protein-synthesis period, preventing the inter-dose troughs that would otherwise slow inter-session recovery and blunt the volume response.

How quickly can I expect training performance to respond when I adjust my Testosterone Propionate dose?

Dose adjustments with a propionate ester translate into altered plasma androgen levels within two to four days. This means a meaningful training-load increase — such as adding a volume block — can be timed with a dose step-up and the combined anabolic signal is detectable within one injection interval, unlike depot esters that require two to three weeks for full plasma redistribution.

How many doses does a 10ml vial of Test-prop 100 at 100mg/ml provide for a typical training cycle?

At 100mg/ml the vial contains 1,000mg total. A common cycle dose of 300mg per week (three 100mg injections) yields approximately 10 full weeks of use per vial — sufficient to cover a complete accumulation-to-intensification training block without restocking mid-cycle. At 50mg EOD the vial extends to roughly 13–14 weeks.

Does the 100mg/ml concentration make it easier to fine-tune doses during different training phases?

Yes. At 100mg/ml each 0.1ml drawn corresponds to exactly 10mg, meaning dose steps as small as 10–20mg are achievable with a standard 1ml insulin syringe. This granularity is particularly useful during the transition phase, when progressive dose reduction needs to track closely with declining training volume without overshooting the target weekly androgen load. (2) angle_used

Manufacturer

Master Pharma's product portfolio spans three distinct lines — research peptides, selective androgen modulators, and injectable androgenic compounds — each governed by a compound-class-specific documentation framework rather than a single blanket GMP statement. The injectable androgen line, to which Test-prop 100 belongs, carries the most stringent release requirements within the portfolio: every batch must clear two independent analytical gates before distribution is authorised. The first gate is reversed-phase HPLC potency quantification against a certified external Testosterone Propionate reference standard, with the chromatographic result confirming that active content falls within the declared 100mg/ml tolerance band. The second gate is LAL (Limulus Amebocyte Lysate) endotoxin quantification, with the expressed EU/ml value benchmarked against injectable parenteral safety thresholds established in pharmacopoeial guidelines. Both results are documented on the lot Certificate of Analysis, which accompanies the batch through the distribution chain. This three-line portfolio architecture means that the quality infrastructure built for the peptide and SARM lines — including ISO-classified fill environments and 0.22µm sterilising-grade filtration — is carried forward and adapted, not replaced, for the injectable androgen SKUs.